ClinicalTrials.gg
RecruitingNCT06199154Updated Jul 29, 2026

Induction of Labor in Morbidly Obese Patients

An Early Phase 1 interventional study of Misoprostol in Morbid Obesity and Pregnancy, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by University of Maryland, Baltimore · Early Phase 1, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Planned enrollment
23rd of 150
162 · median 39
Started
2024
with 11 others
Phase 1
13 of 213
1 open now
Primary completion
2026-12
later than 11 of 34 live
Registered
198th of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 23rd largest by planned enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 1, reaches primary completion later than 11 of the 34 other live ones, and was the 198th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized control trial is to compare different doses of Misoprostol (25 mcg vs 50 mcg) in induction of labor (IOL) in morbidly obese patients with BMI >40. It is known that morbid obesity is a risk factor for failed IOL and ultimately cesarean delivery (CD.) If the rates of vaginal delivery in this population can improve, then surgical morbidity can be reduced in these patients.

Read the detailed description

The rate of IOL continues to increase, from about 10% in 1990 to 23% in 2018. Patients with BMI >40 are at increased risk for failed IOL and needing a CD. Studies show that morbidly obese patients require higher doses of pitocin and multiple agents to achieve vaginal delivery, but optimal dosing of misoprostol has not been studied as well. Increasing the rate of vaginal delivery in this population will help decrease risk of surgical morbidity.

The investigators plan to conduct a randomized controlled double blinded trial. Patients who are scheduled for induction of labor after 34 weeks gestation, have a BMI >40, and meet all study inclusion criteria will be approached by research personnel during their outpatient appointments. Participants will be randomized to either receive 25 mcg vaginal misoprostol every 4 hours or 50 mcg vaginal misoprostol every 4 hours.

03

Conditions studied

  • Morbid Obesity
  • Pregnancy

Browse trials for

Keywords

  • induction of labor
  • morbid obesity
  • misoprostol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Morbidly obese ( ≥ 40 kg/m2) at admission for induction of labor
  • Speaks English or Spanish
  • Gestational age between 34 weeks and 0 days and 42 weeks and 6 days
  • Age 18 years old or older
  • Viable, single, cephalic fetus
  • Intent to proceed with cervical ripening - cervical exam: dilation \< 5 cm
  • Contractions \< 5 per 10 minutes

Exclusion criteria

Exclusion Criteria:

  • History of cesarean delivery
  • to prostaglandin administration (significant myomectomy, prior cesarean delivery)
  • Contraindication to vaginal delivery (placenta previa, vasa previa, with high viral load)
  • Contraindications to labor (cardiac, neurosurgical, need for cesarean)
  • Age \< 18yo
  • Fetal growth restriction with abnormal umbilical artery Doppler indices
  • Cervical dilation >5 cm
  • Contractions >5 per 10 minutes
  • Significant vaginal bleeding with concern for placental abruption
  • Non-reassuring fetal status or fetal heart rate decelerations
  • Fetal demise or major fetal anomaly
  • Inability to give consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Active comparator
    Control - 25 mcg vaginal misoprostol

    Participants will receive 25 mcg vaginal misoprostol every 4 hours.

    Drug: Misoprostol

  • Experimental
    Intervention - 50 mcg vaginal misoprostol

    Participants will receive 50 mcg vaginal misoprostol every 4 hours.

    Drug: Misoprostol

Interventions

  • Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.

06

What researchers measure

Primary outcomes

  1. Achievement of complete cervical dilation

    Time frame: Start of IOL until complete dilation

Secondary outcomes

  1. Time interval from start of induction of labor (IOL) to complete cervical dilation

    Time frame: Start of IOL until complete dilation

  2. Achievement of 6 cm cervical dilation/active labor

    Time frame: Start of IOL until 6 cm dilation

  3. Time interval from start of IOL to 6 cm cervical dilation/active labor

    Time frame: Start of IOL until 6 cm dilation

  4. Time interval from start of IOL to vaginal delivery

    Time frame: Start of IOL until delivery

  5. Time interval from start of IOL to delivery

    Time frame: Start of IOL until delivery

  6. Incidence of vaginal deliveries

    Time frame: Start of IOL until delivery

  7. Incidence of cesarean deliveries

    Time frame: Start of IOL until delivery

  8. Indication for cesarean delivery

    Maternal or Fetal

    Time frame: Start of IOL until delivery

  9. Cervical exam at time of cesarean delivery

    Time frame: Start of IOL until delivery

  10. Number of patients with tachysystole

    Time frame: Start of IOL until delivery

  11. Number of patients with tachysystole with non reassuring fetal heart rate (NRFHT)

    Time frame: Start of IOL until delivery

  12. Number of patients requiring terbutaline

    Time frame: Start of IOL until delivery

  13. Number of patients with chorioamnionitis

    Time frame: Start of IOL until delivery

  14. Number of patients with postpartum hemorrhage

    Time frame: Start of IOL until discharge, assessed up to 4 days

  15. Composite maternal morbidity (need for transfusion, sepsis, ICU admission, death)

    Time frame: Start of IOL until postpartum day 4

  16. Composite neonatal morbidity (NICU admission, Apgar score =<7 at 5 minutes, sepsis, cord gas arterial pH <7.10 and/or base deficit < -12, active cooling protocol, death)

    Time frame: Start of IOL until discharge or day of life 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hoyert, Donna L. "Maternal Mortality Rates in the United States, 2021." Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 16 Mar. 2023, www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.htm.
  • MarchofDimes. "Total Cesarean Deliveries by Maternal Race/Ethnicity: United States, 2019-2021 Average." March of Dimes | PeriStats, www.marchofdimes.org/peristats/data?reg=99&top=8&stop=356&lev=1&slev=1&obj=1. Accessed 14 Nov. 2023.
  • "Adult Obesity Facts." Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 17 May 2022, www.cdc.gov/obesity/data/adult.html.
  • Ellis JA, Brown CM, Barger B, Carlson NS. Influence of Maternal Obesity on Labor Induction: A Systematic Review and Meta-Analysis. J Midwifery Womens Health. 2019 Jan;64(1):55-67. doi: 10.1111/jmwh.12935. Epub 2019 Jan 16. PubMed 30648804 ↗
  • Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett G, Hill K, Thom EA, El-Sayed YY, Perez-Delboy A, Rouse DJ, Saade GR, Boggess KA, Chauhan SP, Iams JD, Chien EK, Casey BM, Gibbs RS, Srinivas SK, Swamy GK, Simhan HN, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med. 2018 Aug 9;379(6):513-523. doi: 10.1056/NEJMoa1800566. PubMed 30089070 ↗
  • Beckwith L, Magner K, Kritzer S, Warshak CR. Prostaglandin versus mechanical dilation and the effect of maternal obesity on failure to achieve active labor: a cohort study. J Matern Fetal Neonatal Med. 2017 Jul;30(13):1621-1626. doi: 10.1080/14767058.2016.1220523. Epub 2016 Aug 25. PubMed 27560557 ↗
  • O'Dwyer V, O'Kelly S, Monaghan B, Rowan A, Farah N, Turner MJ. Maternal obesity and induction of labor. Acta Obstet Gynecol Scand. 2013 Dec;92(12):1414-8. doi: 10.1111/aogs.12263. PubMed 24116732 ↗
  • Pevzner L, Powers BL, Rayburn WF, Rumney P, Wing DA. Effects of maternal obesity on duration and outcomes of prostaglandin cervical ripening and labor induction. Obstet Gynecol. 2009 Dec;114(6):1315-1321. doi: 10.1097/AOG.0b013e3181bfb39f. PubMed 19935035 ↗
  • Drummond R, Patel M, Myers M, Ritter A, Hurvitz JA, Goetzinger KR, Crimmins SD. Class III obesity is an independent risk factor for unsuccessful induction of labor. AJOG Glob Rep. 2022 Sep 23;2(4):100109. doi: 10.1016/j.xagr.2022.100109. eCollection 2022 Nov. PubMed 36311296 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Jan 10, 2024
StartActual
Jul 15, 2024
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06199154
Responsible party
Sponsor
First posted
Jan 10, 2024
Start date
Jul 15, 2024
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Rosa Drummond, MD
Contact
rosa.drummond@umm.edu
4103285965
Krista Mehlhaff, DO
Contact
KMehlhaff@som.umaryland.edu
4103285965

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Misoprostol

Start the discussion